Timing of pembrolizumab infusions for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial looks at how the timing of pembrolizumab (an immunotherapy) infusions affects how well it works against triple-negative breast cancer when given before surgery along with chemotherapy. The goal is to learn if giving the infusion at a certain time of day improves treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female.
- You are 18 years old or older.
- You have triple-negative breast cancer (TNBC) that has not spread to other parts of the body.
- You have received at least one dose of pembrolizumab (Keytruda) along with chemotherapy.
- Your nurse recorded the time of your pembrolizumab infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether the time of day you receive chemotherapy and pembrolizumab (immunotherapy) affects how well they work against triple-negative breast cancer. It's for people who will get these treatments before surgery.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests if continuing pembrolizumab after surgery can help prevent breast cancer from coming back in people with triple-negative breast cancer who still had some cancer after initial chemo and pembrolizumab before surgery.
Hear when a new Non-Metastatic Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.